Gene-Editing Death Rocks Biotech: Trillion-Virus Trial Under Investigation
The death of a young patient in a Chinese gene-editing trial, hidden from a subsequent Nature publication, sends shockwaves through the biotech sector. Industry leaders must grapple with the implications for gene therapy research integrity, funding, and the race to deliver transformative neurological treatments.
Source: channelnewsasia.com · straitstimes.com